Analyst Ratings for Prelude Therapeutics (PRLD)
PRLD Rating Summary
PRLD Price Target Summary
- Highest: $10.00 (Jefferies)
- Lowest: $6.00 (Citizens)
- Average: $8.25
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$8.25 (+91%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 52%
Avg. $ Target:
$8.25 (+91%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 52%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/15/2026 | Goldman Sachs | Corinne Johnson | New Coverage | Early-Stage Biotech (N/A) |
N/A (N/A) |
4.47 (4.32) |
-3.36% | Details |
| 5/4/2026 | D. Boral Capital | Jason Kolbert | New Coverage | Buy (N/A) |
9.00 (N/A) |
4.70 (4.32) |
-8.09% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
